About Saras Capital
Saras Capital is a venture capital firm founded in 2020. It is primarily based out of Canterbury, United Kingdom. As of Nov 2025, Saras Capital is an active investor, having invested in 10 companies, with 4 new investments in the last 12 months. It primarily invests in Seed round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Seed round of Cellbyte A lot of funds co-invest with Saras Capital, with names like SynBioVen sharing a substantial percentage of its portfolio.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 1 more
Portfolio Soonicorns
Deals in last 12 months
Saras Capital's List of Top Investments
Saras Capital has a portfolio of 10 companies. Their most notable investments include Parse Biosciences and INFINITOPES.Their portfolio spans across United States, France, United Kingdom and 3 more locations. They have invested in Life Sciences, Enterprise Applications, High Tech and 3 other sectors, across stages such as Seed, Series A and 1 more. Here is the list of top investments by Saras Capital:Developer of RNA-sequencing solution-based transcriptome kit to analyze health data. It offers solutions that empower researchers to run fixed samples collected on different dates together in a single experiment by providing control over sample handling and reducing errors. The kit uses barcoding to label single cells or single-nucleus suspension for sequencing as well as the tools for data analysis.
Key facts about Parse Biosciences
- Founded Year: 2018
- Location: Seattle (United States)
- Stage: Series C
- Total Funding till date: $100M
- Employee Count: 135 as on Jun 30, 2026
- Investors: Marshall Wace, Janus Henderson Investors and 8 Others
- Latest Funding Round: Series C, Dec 14, 2023, $*****
- Highlight: Editors' Pick
2. INFINITOPES
Developer of vaccines for the treatment of cancer. It offers a VTP-600 immunotherapy vaccine candidate, for patients with non-small cell lung cancer. It stimulates the immune system to produce sustained levels of CD8+ T cells for cancers that produce the two targeted antigens, which include NSCLC
Key facts about INFINITOPES
- Founded Year: 2021
- Location: Iceland
- Stage: Seed
- Total Funding till date: $35.1M
- Employee Count: 29 as on Jun 30, 2026
- Investors: Amplify Partners, Kindred Capital and 12 Others
- Latest Funding Round: Seed, Jan 21, 2026, $*****
- Highlight: Editors' Pick
3. Converge
Developer of GenAI computational tools for drug discovery and manufacturing. The company offers a bio-LLM library with foundation models across biological languages. These models are enhanced with curated data and fine-tuned on task-specific datasets. The platform is deployed through an application layer focused on prediction, explainability, and generation. It provides AI-driven antibody discovery and optimization, protein yield maximization, and cellular response prediction. The platform ensures data privacy and security, offering complete control and fully managed infrastructure.
Key facts about Converge
- Founded Year: 2024
- Location: Wilmington (United States)
- Stage: Series A
- Total Funding till date: $30.5M
- Employee Count: 52 as on Jun 30, 2026
- Investors: Vintage Investment Partners, Gates and 3 Others
- Latest Funding Round: Grant (prize money), Jun 01, 2026, $*****
- Highlight: Editors' Pick
4. Flexciton
Developer of production planning and scheduling software for semiconductor manufacturing. This technology utilizes mathematical optimization and dynamic capacity modeling to manage wafer fabrication processes. The software automates decision-making for toolset scheduling, production planning, and factory-wide operations. It coordinates lot movement and resource allocation to improve throughput, reduce cycle times, and manage production constraints. The system integrates with existing factory infrastructure to provide real-time adjustments to manufacturing schedules based on operational variables and demand requirements.
Key facts about Flexciton
- Founded Year: 2016
- Location: London (United Kingdom)
- Valuation: $*****
- Stage: Series A
- Total Funding till date: $29M
- Employee Count: 41 as on Jun 30, 2026
- Investors: Romulus Capital, Entrepreneur First and 28 Others
- Latest Funding Round: Grant (prize money), Oct 01, 2024, $*****
- Highlight: Editors' Pick
5. Kyron.bio
Developer of bioproduction platform for drug discovery and development. It offers a platform that offers a technology that enables the yield of therapeutic proteins produced in mammalian cell factories by harnessing efficient processes from diverse organisms to revolutionize drug production.
Key facts about Kyron.bio
- Founded Year: 2022
- Location: Paris (France)
- Stage: Seed
- Total Funding till date: $7.51M
- Employee Count: 9 as on Jun 30, 2026
- Investors: Verve Ventures, Entrepreneur First and 3 Others
- Latest Funding Round: Seed, May 28, 2025, $*****
- Highlight: Editors' Pick
Saras Capital's Year-on-Year Investment Trends
Saras Capital has invested in 10 companies over the last 4 years, with an average of 3 new investments annually in the last 3 years. In 2025, it made 5 investments. Its most recent first time investment was in Cellbyte.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 5 | 0 | 5 |
2024 | 2 | 0 | 2 |
2023 | 1 | 0 | 1 |
2022 | 1 | 0 | 1 |
Saras Capital's Investments by Stage
Saras Capital has made 7 investments in Seed stage with an average round size of $9.27M, 1 investment in Series A stage with an average round size of $25M and 1 investment in Series C stage with an average round size of $50M.Stage of entry | No. of Investments |
|---|---|
Seed | 7 |
Series A | 1 |
Series C | 1 |
Note: We have considered here, only first round of investments
Saras Capital's Investments by Sector
Saras Capital has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications, Healthcare and High Tech. Notably, it has invested in 7 Enterprise (B2B) companies, 7 Tech companies, 3 Software companies and at least 1 company focusing on AI-Native.Sector | No. of Investments |
|---|---|
Life Sciences | 7 |
HealthTech | 3 |
Enterprise Applications | 2 |
Healthcare | 2 |
High Tech | 2 |
Others | 1 |
Note: We have considered here, only first round of investments
Saras Capital's Investments by Geography
Saras Capital has made most investments in United States (3), followed by France where it has made 2 investments.Country | No. of Investments |
|---|---|
United States | 3 |
France | 2 |
Germany | 1 |
Iceland | 1 |
Ireland | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Saras Capital's recent investments
Saras Capital has not made any investment in 2026 so far.Here are the most recent investments by Saras Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Nov 19, 2025 | Germany | Seed | 8341 | [+3] | |
Nov 12, 2025 | United States | Seed | 9522 | [+6] | |
Oct 01, 2025 | Ireland | Seed | 4653 | [+8] | |
Sep 24, 2025 | United States | Series A | 8368 | ||
May 28, 2025 | France | Seed | 2674 | [+3] |
Co-investors of Saras Capital
Over the past 4 years, 62 investors have co-invested in Saras Capital's portfolio companies. This includes funds and angels.
- Invested before Saras Capital: Planetary Technologies, Soleus Capital and 7 others have invested in rounds before Saras Capital. There is 1 company where Planetary Technologies has invested before Saras Capital and 1 company where Soleus Capital has invested before Saras Capital.
- Top Co-investors of Saras Capital: 47 investors entered a company along with Saras Capital. These include investors like SynBioVen (2 companies).
- Invested after Saras Capital: A total of 6 investors have invested in Saras Capital's portfolio after their investments. Top Investors include Amplify Partners (1 company), Macmillan Cancer Support (1 company) and Gates (1 company).
Recent News related to Saras Capital
•
Converge Bio secures $25M to democratize generative AI drug discovery for biotech, pharmaPR Newswire•Jan 13, 2026•Converge, Bessemer Venture Partners, Sitewiz, Meta and 7 others
•
Modulight Biotherapeutics Announces $12 Million Seed Funding for Novel Optogenetic Therapy to Treat Neurological Disordersintelligence360•Dec 01, 2025•Jibe Ventures, Redseed, Modulight Biotherapeutics, SilverArc Capital and 5 others
•
Modulight Biotherapeutics Secures $12 Million Seed Funding for Optogenetic TherapyPR Newswire•Nov 12, 2025•Jibe Ventures, LocalGlobe, Modulight Biotherapeutics, Saras Capital and 10 others
•
Avallon Raises $4.6M in Seed FundingFinSMEs•Nov 06, 2025•Avallon, Booom, 1984 Ventures, Y Combinator and 13 others
•
Novoflow, founded by a college dropout, raises $3.1 million in funding for its medical AI.Wowtale•Nov 04, 2025•Novoflow, Y Combinator, Saras Capital, Cellbyte and 3 others
•
Generare snaps €5M to discover next-gen medicines hiding in bacteriaTech Funding News•Oct 08, 2024•Generare, Teampact Ventures, Galion.exe, Vives Fund and 3 others
•
•
Parse Biosciences raises $50M for single cell sequencing techGeekWire•Dec 14, 2023•Parse Biosciences, Soleus Capital, Bioeconomy Capital, Janus Henderson Investors and 4 others
•
